Clinical Trials
25 trialsNCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04068831 2024-12-27
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04173507 2024-09-03
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT03343054 2024-08-22
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03148795 2024-04-05
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 2 Completed
NCT05141708 2024-02-16
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Pfizer
Completed
NCT04987931 2024-01-22
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
Pfizer
Completed
NCT04635631 2023-10-10
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Pfizer
Phase 1 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT02401347 2023-02-21
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Stanford University
Phase 2 Completed
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT02282345 2022-07-06
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01945775 2022-01-20
EMBRACA
Pfizer
Phase 3 Completed
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03377556 2021-06-23
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02116777 2021-03-26
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02997176 2021-02-25
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
Phase 1 Completed
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT03042910 2019-12-17
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed